Search academic texts

Information × Registration Number 0222U003718, 0120U002186 , R & D reports Title Optimization of conservative treatment of HER2 / neu breast cancer patients (negative) at high risk of disease progression. popup.stage_title Head Syvak Lubov А., Доктор медичних наук Registration Date 25-05-2022 Organization National Cancer Institute popup.description2 Object of study: HER2neu breast cancer negative. Research methods: general clinical, instrumental, morphological, immunohistochemical, molecular genetic, methods of medical informatics, descriptive epidemiology, mathematical statistics. The aim is to increase the effectiveness of treatment of patients with Her2 / neu negative breast cancer by optimizing the comprehensive treatment of high risk groups for disease progression, taking into account the biological characteristics of the tumor, its microenvironment and immunoreactivity. 103 patients with breast cancer II A - III B were treated: II A Art. had - 21 (20%) patients, II B art. - 46 (45%), III A art. - 31 (30%) and III B Art. - 5 (5%) patients, aged 25 to 71 years, the average age was 53 years, of which: up to 40 years there were 49, over 40 years - 54 patients. Conducting IHC examination of tumor samples before treatment allowed to diagnose luminal A subtype of breast cancer in 57 patients, luminal B - in 25, three times negative breast cancer - in 21 patients. The expression of TKS4 - TKS4 and TKS4b mRNA isoforms was analyzed by real-time PCR in 36 tumor samples from patients with RGD: in 13 patients with luminal A breast cancer, 11 in patients with luminal B breast cancer and in 12 patients with TNRG. A statistically significant increase in both the total content of mRNA transcripts of the TKS4 gene and its isoforms of TKS4b in tumor tissue compared with non-tumor tissues (p <0.05). In addition, TNRG tumor tissue had a higher total content compared to luminal subtypes of breast cancer (p> 0.05), which requires further research. The expression of intersectin 2 gene isoforms (ITSN2) was studied: the content of short (ITSN2-S) and long (ITSN2-L) ITSN2 isoforms was determined, as well as the ratio of the amount of short ITSN2 isoform to the amount of long (ITSN2-S / ITSN2-L) in 42 patients with breast cancer. Product Description popup.authors Verovkina Nataliia O. Danylenko Viktoriia V. Dasiukevich Olga Y. Dzhuzha Dmytro O. Lyalkin Serhii А. Martynyuk Olena M. Orel Valeriy E. Rykhalskyy Oleksandr Yu Solodyannykova Oksana I. Tarasenko Tetyana Ye Filchakov Feodosiy V. Yatsenko Lyudmyla D. popup.nrat_date 2022-05-25 Close